High Compliance and regulatory risk, coupled with steep production costs, unending power cuts, and import-related costs for pharmaceutical products and raw materials, have stifled growth in the local pharmaceutical manufacturing and retail sector, Industry players have said. By Michael Gwarisa The high costs of doing business have had a ripple effect on the consumers as the cost of pharmaceutical products locally is beyond the reach of many and in some cases, has led to drug stock-outs as operators struggle to produce and procure pharmaceutical products from source markets. Speaking at…
Read MoreZimbabwe’s Pharmaceutical Industry On Chokehold
